Are new antiretroviral treatments increasing the risks of clinical obesity?

There is growing evidence that the use of integrase inhibitors could lead to statistically significant increases in body weight and even clinical obesity, although it is unclear whether these changes are clinically significant. The effects of integrase inhibitors on body weight need to be analysed f...

Full description

Saved in:
Bibliographic Details
Published inJournal of Virus Eradication Vol. 5; no. 1; pp. 41 - 43
Main Authors Hill, Andrew, Waters, Laura, Pozniak, Anton
Format Journal Article
LanguageEnglish
Published England Mediscript Ltd 01.01.2019
Elsevier
Subjects
antiretroviral therapy
bictegravir
dolutegravir
integrase inhibitors
obesity
raltegravir
Viewpoint
raltegravir
bictegravir
integrase inhibitors
dolutegravir
antiretroviral therapy
obesity
Online AccessGet full text

Cover

More Information
Summary:There is growing evidence that the use of integrase inhibitors could lead to statistically significant increases in body weight and even clinical obesity, although it is unclear whether these changes are clinically significant. The effects of integrase inhibitors on body weight need to be analysed for women and by race, because current evidence suggests different effects. Potential additional effects of NRTIs on body weight need to be evaluated. Combined, standardised analyses of Phase 3 and independent clinical trials, with endpoints following the US Food and Drug Administration (FDA) guidelines where feasible, should be conducted to answer this question definitively. Analyses should also include a range of laboratory markers of cardiovascular risk, as proposed by the FDA.
Bibliography:SourceType-Other Sources-1
content type line 63
ObjectType-Editorial-2
ObjectType-Commentary-1
ISSN:2055-6640
2055-6659
DOI:10.1016/s2055-6640(20)30277-6